Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).

被引：8

作者：

Arnold, Dirk

Graeven, Ullrich

Lerchenmuller, Christian A.

Killing, Brigitta

Depenbusch, Reinhard

Steffens, Claus-Christoph

Al-Batran, Salah-Eddin

Lange, Thoralf

Dietrich, Georg

Stoehimacher, Jan

Tannapfel, Andrea

Schmoll, Hans-Joachim

Reinacher-Schick, Anke

Hegewisch-Becker, Susanna

机构：

[1] Klin Tumorbiol, Freiburg, Germany

[2] Kliniken Maria Hilf, Monchengladbach, Germany

[3] Lahn Dill Kliniken, Wetzlar, Germany

[4] MVZ Haematol & Oncol, Stade, Germany

[5] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[6] Asklepios Klinikum, Weissenfels, Germany

[7] Krankenhaus Bietigheim, Bietigheim Bissingen, Germany

[8] Kooperat Tumordiagnost, Inst Tumorgenet, Bonn, Germany

[9] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany

[10] Univ Hosp, Oncol & Hematol, Halle, Germany

[11] Ruhr Univ Bochum, St Joseph Hosp, Bochum, Germany

[12] HOPE, Hamburg, Germany

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3503

引用

页数：1